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ABSTRACT
Objectives: To compare health-related and cost-related
outcomes of consultations for symptoms suggestive of
minor ailments in emergency departments (EDs),
general practices and community pharmacies.
Design: Observational study; prospective cohort
design.
Setting: EDs (n=2), general practices (n=6) and
community pharmacies (n=10) in a mix of rural/urban
and deprived/affluent areas across North East Scotland
and East Anglia. Participants Adults (≥18 years)
presenting between 09:00 and 18:00 (Monday–Friday)
in general practices and 09:00–18:00 (Monday–
Saturday) in pharmacies and EDs with ≥1 of the
following: musculoskeletal pain; eye discomfort;
gastrointestinal disturbance; or upper respiratory
tract-related symptoms.
Interventions: Participants completed three
questionnaires: baseline (prior to index consultation);
satisfaction with index consultation and follow-up
(2 weeks after index consultation).
Main outcome measures: Symptom resolution,
quality of life, costs, satisfaction and influences on
care-seeking behaviour.
Results: 377 patients participated, recruited from EDs
(81), general practices (162) and community
pharmacies (134). The 2-week response rate was 70%
(264/377). Symptom resolution was similar across all
three settings: ED (37.3%), general practice (35.7%)
and pharmacy (44.3%). Mean overall costs per
consultation were significantly lower for pharmacy
(£29.30 (95% CI £21.60 to £37.00)) compared with
general practice (£82.34 (95% CI £63.10 to £101.58))
and ED (£147.09 (95% CI £125.32 to £168.85)).
Satisfaction varied across settings and by measure
used. Compared with pharmacy and general practice
use, ED use was significantly (p<0.001) associated with
first episode and short duration of symptom(s), as well
as higher levels of perceived seriousness and urgency
for seeking care. Convenience of location was the most
common reason for choice of consultation setting.
Conclusions: These results suggest similar health-
related outcomes and substantially lower costs with
pharmacy consultations for minor ailments. Effective
strategies are now needed to shift demand for minor
ailment management away from EDs and general
practices to the community pharmacy setting.
INTRODUCTION
Emergency departments (EDs) are reported
to be in crisis1 with 22 million attendances in
EDs in England between 2012 and 2013, one
third of which involved ‘guidance or advice
only’.2 This is placing ‘intense, growing and
unsustainable pressure’ on the service.3
In general practice, 340 million general prac-
tice consultations occurred between 2012 and
2013.3 This equates to an estimated 5.5 consul-
tations per patient annually; 40% higher than
1995.4 Recent estimates suggest that 5% and
13% of consultations in ED and general prac-
tice, respectively, are for minor ailments that
could be managed in community pharmacies.5
Strengths and limitations of this study
▪ This is the first study to compare health-related
and cost-related outcomes across the three main
healthcare settings where patients present with
symptoms suggestive of minor ailments.
▪ Prospective data collection using the same pro-
cesses and tools across all three settings
reduces the risk of bias.
▪ While the inclusion of different types of pharmacies
and a variety of locations of pharmacies and general
practices increased the generalisability of the results,
more rural communities were under-represented.
▪ A cohort study design was used rather than a
randomised controlled trial because the latter
was an impractical option to address the objec-
tives of this study.
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For the purpose of this study, minor ailments are
“common or self-limiting or uncomplicated conditions
which may be diagnosed and managed without medical
(ie, doctor) intervention.”6
The above illustrates that health seeking for the man-
agement of minor ailments from high-cost settings such
as EDs and general practice persists despite a wide range
of alternative sources of care being widely available.
Effective over-the-counter (OTC) medicines can be sup-
plied from community pharmacies to support the man-
agement of minor ailments.7 Over the past 30 years,
many medicines have been reclassiﬁed from ‘prescription
only’ status to OTC medicines and this has increased the
options available for the treatment of minor ailments.
Local and national pharmacy-based minor ailment
schemes have also been introduced to reduce demand
on high-cost settings, with evidence from a recent system-
atic review suggesting that they appear to be effective.8
Pharmacy-based minor ailment schemes provide public
access to NHS treatment and/or advice via a pharmacist
or pharmacy personnel, or, where appropriate, to onward
referral to other health professionals. These schemes
were originally proposed by the UK health departments
as part of their long-term strategy to encourage patient
self-care and utilisation of pharmacies as the ﬁrst port of
call for minor ailments where professional support was
required. However, the evidence to date is limited in
terms of study quality and outcomes reported, that is,
generally surrogate health outcomes have been evalu-
ated, such as reconsultation rates. Furthermore, no
formal economic evaluations have been reported.
There is an urgent need to shift demand for minor
ailment management from high-cost settings to potentially
cheaper alternatives, for example, community pharmacies.
Reassurance, however, is needed that similar outcomes can
be achieved with community pharmacy management com-
pared with these other settings. The purpose of this study
was to compare health-related and cost-related outcomes
associated with the management of symptoms suggestive
of minor ailments (hereafter referred to as minor ail-
ments) in three healthcare settings: ED, general practice
and community pharmacy. The following objectives were
assessed:
1. Whether health-related and cost-related outcomes
differ between settings.
2. Whether satisfaction with index consultation is asso-
ciated with health-related outcomes.
3. What factors (triggers) inﬂuence patients’ choice of
care setting.
METHODS
Study design
A prospective cohort study was conducted.
Study setting and recruitment
The study was conducted across two geographic regions
(East Anglia, England and Grampian, Scotland).
Potential participating sites were identiﬁed using NHS
lists of health service providers. General practices and
community pharmacies were eligible if they were within
a 25-mile radius of the main city in East Anglia
(Norwich) and Grampian (Aberdeen). This was to
ensure that participants could realistically have chosen
from all three settings of interest. In Grampian, a letter
of invitation was sent to all eligible practices and phar-
macies. In East Anglia, the same approach was used for
pharmacies. From those expressing an interest (online
supplementary appendix 1), purposive sampling was
used to generate a maximum variation sample to
include different types and locations of pharmacies and
different locations of general practices. Three general
practices were purposively selected in East Anglia to
achieve maximum variation.
Participant recruitment
Participant recruitment was undertaken by six researchers
between July 2012 and April 2013. The same process for
data collection was used across all settings. Participants
were eligible for inclusion if they: were aged ≥18 years;
requested treatment for one or more of the four included
minor ailments or presented symptoms associated with
these ailments; requested medicines for the treatment of
one of the four minor ailments (pharmacy only); pre-
sented between 09:00 and 18:00, Monday–Saturday
(ED and pharmacy) and between 09:00 and 18:00,
Monday–Friday (general practice); had a face-to-face con-
sultation (ie, interaction with member of staff). This con-
sultation is referred to hereafter as the ‘index
consultation’. These recruitment periods were selected to
reﬂect the traditional opening hours of community phar-
macies (ie, to reﬂect periods when patients had the option
of seeking care from community pharmacies if they had
chosen to do so). Patients in pharmacies were excluded if
they were collecting prescription items for target minor ail-
ments or purchasing treatment for the future manage-
ment of those ailments. Patients in any setting were
excluded if they did not adequately understand verbal/
written information in English. The same recruitment
method was used across all sites and settings. Promotional
posters were displayed throughout participating sites.
Receptionists (ED and general practice) and pharmacy
staff could also direct potential participants to the
researchers who were based within each premises. The
researchers were not permitted to approach patients dir-
ectly due to the NHS Ethics Committee’s decision. The
researchers applied the inclusion criteria and sought
informed consent from all eligible and willing patients.
The four included symptoms/ailments were:
▸ Musculoskeletal pain: aches or pain in arms or legs
or back or hands or feet;
▸ Eye discomfort;
▸ Gastrointestinal disturbance: nausea or vomiting or
diarrhoea or constipation;
▸ Upper respiratory tract-related: sore throat or cough
or cold or sinus problems.
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The above groups of symptoms were chosen because
they have previously been identiﬁed as occurring fre-
quently within EDs and general practices.5
Data collection
Data collection was undertaken using the same process
across all settings to minimise bias. Participants were
asked to self-complete three questionnaires; one at base-
line prior to the consultation, one immediately after the
consultation and one two weeks later. The content of
the questionnaires was informed by the literature and
also comprised a range of validated (EQ-5D/EQ-VAS
(visual analogue scale),9 MISS-21 (Medical Interview
satisfaction Scale),10 triggers for seeking care11) and
non-validated measures (global satisfaction very satisﬁed/
dissatisﬁed (5-point)). The MISS-2110 was developed to
use with consultations in general practice. The items
were rephrased to ensure face validity for their use with
participants recruited from the EDs and community
pharmacies. The scale comprises four subscales: distress
relief; communication; rapport and compliance intent.
The urgency for seeking care and perceived severity
items were derived from previous research.12 13
The purpose of the baseline questionnaire was to
collect basic demographics, triggers for seeking care and
contact details for follow-up. Baseline information was
also collected on potential predictors or confounders
and included the index minor ailment, age, gender,
employment status, marital status, living alone, whether
it was the ﬁrst time they had experienced the symptoms,
how serious the symptoms were perceived to be, belief
on timing of visit, how long they had had the ailment,
and baseline EQ-5D visual analogue scale (EQ-VAS).
The postconsultation questionnaire asked about satis-
faction (global satisfaction and MISS-21), the outcome
of the consultation (eg, medicines sold or supplied) and
associated costs. The 2-week follow-up questionnaire
asked participants about symptom resolution, quality of
life, re-consultation for the index ailment and health
service utilisation since their index consultation.
One version was used for each setting (ED, general
practice, community pharmacy) and differed only in site-
speciﬁc questions relevant to the triggers for seeking
care. Although developed for self-completion, if asked to
do so, a researcher would assist participants in complet-
ing the baseline and/or satisfaction questionnaires by
reading the questions and response options to the partici-
pant. Participants were permitted to take the postconsul-
tation questionnaire away with them (with a reply-paid
envelope) for later completion if necessary. Follow-up
questionnaires were mailed to participants. They were
given the option of self-completing these and returning
them by mail or completing it with a researcher over the
phone. Those opting for mailed questionnaires were sent
reminders at 2 and 4 weeks after the initial mailing. The
study processes and documentation (questionnaires)
were piloted over a 3.5-day period and included 28
patients recruited from one pharmacy (n=3), one
general practice (n=11) and the ED (n=14) in Grampian.
Changes were made to the promotional materials and
questionnaires as a result of piloting.
Exposure and outcomes
The exposure of interest was setting of care: ED, general
practice or pharmacy. The primary outcome was
symptom resolution 2 weeks after the index consultation.
Secondary outcomes (collected in the postconsultation
questionnaire) were: sold or supplied medicines, satisfac-
tion measured by MISS-21,10 participant experience,
duration of consultation and quality of life (QoL) mea-
sured by the EQ-5D-3L.14 Triggers for choice of site of
presentation are reported as a secondary outcome from
the baseline questionnaire.
Sample size
A symptom resolution rate of 70% was assumed based
on a previous estimate.15 A minimum of 81 participants
were required per setting. The prevalence of minor ail-
ments was anticipated to be higher in community phar-
macies and general practices5 compared with EDs. As
such, recruitment targets for the higher prevalence sites
were set at 160 participants and from the EDs were 80.
Based on these estimates, the study would have over
80% power at a 5% level to detect differences of 10%
between symptom resolution rates of 70% (95% CI 60%
to 80%) across settings.
Statistical methods and analysis
Data were entered into an IBM SPSS Statistics V.20 data-
base and a 10% random sample checked for accuracy.
Categorical variables were described with frequency and
valid percentages. Normally distributed continuous vari-
ables were summarised using mean and SD with median
and IQR provided if data were skewed. Comparison of
categorical variables between sites of presentation (ED,
general practice, pharmacy) was undertaken using χ2
tests or Fisher’s exact test where required. Comparison of
continuous variables between sites was undertaken using
analysis of variance (ANOVA) if normally distributed and
Kruskal-Wallis if skewed. Logistic regression was used to
ascertain predictors of binary outcomes (eg, symptom
resolution). Linear regression was used to model QoL
(EQ-5D) at follow-up. Variables were included in these
models if signiﬁcant (p≤0.05) in the univariate analysis
(independent t-test, ANOVA, correlation as appropriate)
or belonged to an a priori list of variables for inclusion
(site, ailment, age, gender, baseline EQ-5D and duration
of symptoms). All analyses were undertaken on complete
cases for that outcome.
For each participant, costs were estimated for the
index consultation and any actions taken in the next
2 weeks for the original minor ailment in question
(health professional contacts, medication and investiga-
tions). Both NHS and any patient out of pocket costs
(for medication only) were included. Costs were esti-
mated in UK sterling (£) at 2011/2012 ﬁnancial year
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levels, but not discounted as the time frame was less
than 1 year. A complete case approach16 was adopted at
each time point. Thus, costs were only estimated if data
were available for each aspect of resource use for the
index consultation/follow-up questionnaire. Cost per
participant was estimated by summing the index consult-
ation cost and the costs incurred in the 2 weeks there-
after. To estimate the impact of the index consultation
on health-related QoL, participants were asked to com-
plete the EuroQoL EQ-5D-3L14 at baseline and 2-week
follow-up. This enabled a cost-utility analysis to be under-
taken. Quality adjusted life year (QALY) scores were only
calculated for those with complete baseline and
follow-up EQ-5D-3L scores, and it was assumed scores
changed linearly between these two time points.17
STATAV.11 was used for all economic analyses; p values
≤0.05 were deemed statistically signiﬁcant. Multiple
linear regression17 with backward stepwise selection was
used to estimate the mean cost difference (incremental
cost) between the three settings and the mean QALY dif-
ference (incremental effect). Individuals with missing
data for any of the covariates in the ﬁnal model were
excluded. If care in one setting did not dominate the
care provided in the other two settings,18 the incremental
cost per QALY gain (incremental cost-effectiveness ratio
(ICER)) was calculated (mean incremental cost/mean
incremental QALY gain) by comparing each remaining
setting with the next cheapest. In line with National
Institute for Health and Care Excellence (NICE) guid-
ance,19 any calculated ICER would be compared with a
cost-effectiveness threshold (λ) of £20 000 per QALY.
Subgroup analysis
Resolution of symptoms was compared separately across
sites for each minor ailment (where numbers permit-
ted). QoL outcomes (EQ-5D-3L utility and EQ-VAS), par-
ticipant experience and MISS-21 scales at baseline and
follow-up were compared separately within site for indivi-
duals whose symptoms did and did not resolve.
RESULTS
Setting characteristics
Two EDs, 6 general practices and 10 community phar-
macies participated, equally distributed across the two
regions. Both EDs were located in teaching hospitals. Of
the 10 pharmacies, 6 were large chain, 2 small-chain and
2 independent single outlets. Four general practices
were in urban areas. The pharmacies and practices were
located across a range of deprivation codes (online
supplementary appendix 1).
Participant characteristics
In total 377 participants were recruited, 94.3% of the target
sample size (n=400; table 1). Of these, 81, 162 and 134
were recruited from EDs, general practices and community
pharmacies, respectively. Thus target recruitment was met
for general practice and ED. Participant characteristics by
setting are shown in table 1. Participants recruited from
community pharmacies were signiﬁcantly older than those
recruited elsewhere. ED participants were signiﬁcantly
younger and more likely to be single compared with parti-
cipants recruited in general practices and pharmacies.
Most participants presented with musculoskeletal aches
and pains (46.4%, n=175) or upper respiratory tract
symptoms (28.9%, n=109). Presenting condition varied
across settings, for example, musculoskeletal symptoms
dominated in ED (81.5%, n=66; table 1). In total, 39.2%
(n=147) of participants were experiencing the symptom
for the ﬁrst time (64.2% (n=52) in ED, 38.8% (n=62) in
general practices and 24.6% (n=33) in pharmacies).
Participants recruited from ED were signiﬁcantly more
likely to have had the symptom for a short period of time
prior to their index consultation (median 1 day (IQR
0.5–7.0)) compared with participants in general practice
(median 14 days (IQR 3–42)). ED participants were sig-
niﬁcantly more likely to consider their symptom to be
‘somewhat serious’ compared with participants recruited
from other sites and were signiﬁcantly more likely
(67.5%, (n=52)) to state that they needed to seek care for
their symptom(s) within 24 h compared with general
practice (47.2%, (n=76)) and pharmacy-based partici-
pants (37.9%, (n=50)).
Data from postconsultation questionnaires were avail-
able for 89.7% (338/377) of participants: ED (77.8%,
63/81), general practice (87%, 141/162) and pharmacy
(100%). The follow-up questionnaire was completed by
263 (69.8%) participants: 63% (51/81) ED, 71.6%
(116/162) general practice and 72% (97/134) phar-
macy. The response rates did not differ signiﬁcantly
across the settings (p=0.29).
Health-related outcomes
Primary outcome: symptom resolution
Median follow-up was 17 days (IQR 15–21) and most
(86.1%) participants were followed up within 1 month.
At follow-up, the proportion of symptoms that had
resolved was similar across settings with 37.3% resolving in
ED, 35.7% in general practice and 44.3% in pharmacy
(p=0.415, table 2). Univariate analysis showed that signiﬁ-
cant predictors of symptom resolution were: the type of
presenting symptom, its perceived seriousness, the
urgency with which the participant believed they should
seek help, duration of symptoms and baseline QoL
(table 3). In the adjusted model, signiﬁcant predictors
were: presenting symptom and belief about the urgency
with which they should visit their chosen site (ie, 24 or
>24 h; table 3). Participants who believed they needed to
consult about their symptoms within 24 h were more likely
to report symptom resolution. The odds of resolution were
signiﬁcantly higher for non-musculoskeletal symptoms.
Setting was not a signiﬁcant predictor of resolution.
Secondary outcomes: postconsultation
A signiﬁcantly higher proportion (p<0.001) of partici-
pants was sold, prescribed or supplied medicines from
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Table 1 Characteristics of participants by site including information on the symptoms per cent (n)
Overall
(N=377) ED (N=81)
General
practice
(N=162)
Pharmacy
(N=134) p Value*
Participant demographics
Age
Mean (SD) 48.3 (17.8) 42.2 (17.9) 48.3 (17.6) 51.9 (17.1) 0.001†
Missing (7) (4) (2) (1)
Gender
Male 40.6 (151) 44.9 (35) 40.4 (65) 38.3 (51) 0.646‡
Female 59.4 (221) 55.1 (43) 59.6 (96) 61.7 (82)
Missing (5) (3) (1) (1)
Employment
Employed full-time 60.5 (225) 66.7 (52) 64.6 (104) 51.9 (69) 0.006‡
Retired 22.0 (82) 10.3 (8) 23.6 (38) 27.1 (36)
Other (including student,
unemployed)
17.5 (65) 23.1 (18) 11.8 (19) 21.1 (28)
Missing (5) (3) (1) (1)
Registered MAS§
Yes 10.2 (38) 10.4 (8) 6.2 (10) 15.0 (20) 0.079‡
No 81.1 (301) 84.4 (65) 82.6 (133) 77.4 (103)
Do not know 8.6 (32) 5.2 (4) 11.2 (18) 7.5 (10)
Missing (6) (4) (1) (1)
Marital Status
Single 24.2 (90) 37.2 (29) 22.4 (36) 18.8 (25) 0.012‡
Married/living with partner 61.6 (229) 53.8 (42) 65.2 (105) 61.7 (82)
Divorced/separated/widowed 14.2 (53) 9.0 (7) 12.4 (20) 19.5 (26)
Missing (5) (3) (1) (1)
Live alone
Yes 20.3 (75) 13.2 (10) 18.8 (30) 26.3 (35) 0.061‡
No 79.7 (294) 86.8 (66) 81.2 (130) 73.7 (98)
Missing (8) (5) (2) (1)
Registered with GP in the UK
Yes 97.8 (364) 98.7 (77) 98.1 (158) 97.0 (129) –
No 2.2 (8) 1.3 (1) 1.9 (3) 3.0 (4)
Missing (5) (3) (1) (1)
Nationality
British 94.9 (351) 93.6 (73) 96.2 (153) 94.0 (125) –
Other EU 3.0 (11) 2.6 (2) 3.1 (5) 3.0 (4)
Non-EU 2.2 (8) 3.8 (3) 0.6 (1) 3.0 (4)
Missing (7) (3) (3) (1)
Norfolk only (N=163) (N=35) (N=71) (N=57)
Pay for prescriptions
Yes 51.2 (82) 57.6 (19) 50.0 (35) 49.1 (28) 0.713‡
No 48.8 (78) 42.4 (14) 50.0 (35) 50.9 (29)
Do not know/missing* (3) (2) (1) (0)
Ailment characteristics
Presenting Symptoms
Musculoskeletal aches and pains 46.4 (175) 81.5 (66) 36.4 (59) 37.3 (50) <0.001‡
Eye-related 11.4 (43) 14.8 (12) 11.1 (18) 9.7 (13)
Stomach upset 4.8 (18) 1.2 (1) 6.2 (10) 5.2 (7)
Upper respiratory tract 28.9 (109) 0 (0) 34.0 (55) 40.3 (54)
Multiple symptoms 8.5 (32) 2.5 (2) 12.3 (20) 7.5 (10)
First time had symptoms
Yes 39.2 (147) 64.2 (52) 38.8 (62) 24.6 (33) <0.001‡
No 60.8 (230) 35.8 (29) 61.3 (98) 75.4 (101)
Missing (2) (0) (2) (0)
Continued
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Table 1 Continued
Overall
(N=377) ED (N=81)
General
practice
(N=162)
Pharmacy
(N=134) p Value*
How serious are the symptoms?
Not serious at all 37.0 (136) 16.9 (13) 27.5 (43) 60.2 (80) <0.001‡
Somewhat serious 54.1 (199) 75.3 (58) 61.4 (97) 33.1 (44)
Very serious 9.0 (33) 7.8 (6) 11.4 (18) 6.8 (9)
Missing (9) (4) (4) (1)
How soon did you need to visit?
Within 24 h 48.1 (178) 67.5 (52) 47.2 (76) 37.9 (50) <0.001‡
24 h or more 51.9 (192) 32.5 (25) 52.8 (85) 62.1 (82)
Missing (7) (4) (1) (2)
Duration of symptoms
Median (IQR) in days 7 (2–35) 1.0 (0.5–7.0) 14 (3–42) 7 (2–80) <0.001¶
Baseline EQ-VAS (n=370) (n=76) (n=160) (n=134) 0.455†
Mean (SD) 68.0 (19.6) 68.9 (22.4) 66.6 (18.9) 69.3 (18.8)
*Tests exclude missing data.
†ANOVA.
‡Pearson χ2.
§National MAS (Scotland).
¶Kruskal-Wallis test.
ANOVA, analysis of variance; ED, emergency department; EU, European Union; GP, general practitioner; MAS, Minor Ailment Scheme; VAS,
visual analogue scale.
Table 2 Outcomes: resolution of symptoms, quality of life and outcome of index consultation by setting
Overall % (n) ED % (n)
General
practice % (n) Pharmacy % (n) p Value
Resolution of symptoms at 2-week follow-up (n=263) (n=51) (n=116) (n=97) 0.415*
Resolved 39.2 (103) 37.3 (19) 35.7 (41) 44.3 (43)
Follow-up EQ-VAS (n=261) (n=50) (n=115) (n=96) 0.054†
Mean (SD) 77.4 (18.2) 74.8 (19.6) 75.5 (19.5) 80.9 (15.3)
Change in EQ-VAS (n=259) (n=50) (n=113) (n=96) 0.726†
Mean (SD) 8.43 (18.2) 7.6 (17.9) 7.8 (18.1) 9.6 (18.5)
Outcome of index consultation (n=338) (n=63) (n=141) (n=134)
Sold or supplied medicines (n=334) (n=61) (n=141) (n=132) <0.001*
Yes 66.5 (222) 31.1 (19) 61.7 (87) 87.9 (116)
Sold or supplied items (n=327) (n=59) (n=138) (n=130) <0.001*
Yes 9.3 (35) 37.3 (22) 2.2 (3) 7.7 (10)
Satisfaction (n=334) (n=60) (n=136) (n=127) 0.115*‡
Satisfied 64.7 (209) 53.3 (32) 66.2 (90) 68.5 (87)
Neither 31.9 (103) 45.0 (27) 27.9 (38) 29.9 (38)
Dissatisfied 3.4 (11) 1.7 (1) 5.9 (8) 1.6 (2)
Experience (n=328) (n=61) (n=141) (n=126) 0.011§
Median (IQR) 10 (8–10) 9 (7–10) 10 (8–10) 10 (8–10)
Duration of wait (minutes) (n=334) (n=62) (n=141) (n=131) <0.001§
Median (IQR) 5 (1–30) 47.5 (30–86.25) 15 (5–30) 1 (0–2)
Duration of consultation (minutes) (n=332) (n=61) (n=141) (n=130) <0.001§
Median (IQR) 5 (2–10) 10 (5–27.5) 10 (5–10) 2 (1–3)
MISS 21 items¶ (n=268) (n=63) (n=141) (n=101)
Total score: mean (SD) 5.27 (0.97) 5.39 (0.94) 5.70 (1.01) 4.75 (0.81) <0.001†
Distress relief: mean (SD) 4.97 (1.24) 5.29 (1.14) 5.39 (1.17) 4.31 (1.09) <0.001†
Communication: mean (SD) 5.50 (1.19) 5.43 (1.24) 5.89 (1.16) 5.05 (1.05) <0.001†
Rapport: mean (SD) 5.38 (1.06) 5.48 (1.02) 5.83 (1.32) 4.83 (0.91) <0.001†
Compliance intent: mean (SD) 5.40 (1.10) 5.41 (1.18) 5.69 (1.05) 5.04 (1.02) <0.001†
*Pearson χ2.
†ANOVA.
‡For 2×2 where neither and dissatisfied are combined.
§Kruskal-Wallis test.
¶n is for total score.
ANOVA, analysis of variance; ED, emergency department; MISS 21, Medicine Information Satisfaction Score; VAS, visual analogue scale.
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pharmacies (87.9%) compared with general practice
(61.7%) or ED (31.1%). A higher proportion of partici-
pants was supplied other items (eg, dressings) in ED
(37.3%) compared with being sold or supplied in phar-
macy (7.7%) or prescribed by general practice (2.2%;
table 2).
Satisfaction was assessed using two measures:
MISS-2110 and global (5-point) scale (very satisﬁed/very
dissatisﬁed). MISS-21 total and component scores dif-
fered signiﬁcantly (p<0.001) across settings and were
consistently highest in general practice and lowest in
pharmacy (table 2). While higher satisfaction scores
were achieved using the global measure in pharmacy
(68.5%) and general practice (66.2%) compared with
ED (53.3%), these were not signiﬁcant (p=0.115;
table 2). The duration of wait for the index consultation
was signiﬁcantly longer (p<0.001) in ED compared with
other sites and could have inﬂuenced satisfaction ratings
(table 2).
Secondary outcomes at follow-up: QoL
QoL measured by the EQ-5D visual analogue scale
(EQ-VAS) at follow-up was highest for those who had
visited a pharmacy, but differences between sites were
not statistically signiﬁcant (table 2). Participants who
visited a pharmacy had the greatest observed change in
EQ-VAS compared with baseline (table 2), but this was
not statistically different (p=0.726). Employment status
Table 3 Logistic regression to assess factors associated with symptom resolution
Per cent (n) within variable
Resolved
% (n)
Not resolved
% (n)
Unadjusted Adjusted
OR 95% CI OR 95% CI
Site
Pharmacy 44.3 (43) 55.7 (54) 1.00 1.00
General practice 35.7 (41) 64.3 (74) 0.70 (0.40 to 1.21) 0.72 (0.35 to 1.49)
ED 37.3 (19) 62.7 (32) 0.75 (0.37 to 1.49) 0.97 (0.37 to 2.57)
Presenting symptoms
Musculoskeletal aches/pains 22.9 (27) 77.1 (91) 1.00 1.00
Eye pain/discomfort 73.3 (22) 26.7 (8) 9.27 (3.71 to 23.2) 7.96 (2.93 to 21.6)
Stomach upset 63.6 (7) 36.4 (4) 5.90 (1.61 to 21.7) 7.01 (1.73 to 28.5)
Upper respiratory tract 50.0 (41) 50.0 (41) 3.37 (1.83 to 6.20) 2.80 (1.28 to 6.14)
Multiple symptoms 27.3 (6) 72.7 (16) 1.26 (0.45 to 3.55) 1.70 (0.48 to 6.14)
Gender
Male 43.5 (40) 56.5 (52) 1.00 1.00
Female 37.3 (63) 62.7 (106) 0.77 (0.46 to 1.30) 0.67 (0.35 to 1.27)
Employment
Employed full time 42.0 (63) 58.0 (87) 1.00
Retired 33.8 (24) 66.2 (47) 0.71 (0.39 to 1.27)
Other (including student, unemployed) 40.0 (16) 60.0 (24) 0.92 (0.45 to 1.87)
Marital status
Single 50.0 (25) 50.0 (25) 1.00
Married/living with partner 37.4 (65) 62.6 (109) 0.60 (0.32 to 1.12)
Divorced/separated/widowed 35.1 (13) 64.9 (24) 0.54 (0.23 to 1.30)
Live alone
Yes 40.1 (83) 64.2 (34) 0.84 (0.45 to 1.56)
No 35.8 (19) 59.9 (124) 1.00
First time had symptoms
Yes 41.4 (41) 58.6 (58) 1.18 (0.71 to 1.97)
No 37.4 (61) 62.6 (102) 1.00
How serious are the symptoms?
Not serious at all 49.0 (48) 51.0 (50) 1.00 1.00
Somewhat/very serious 33.3 (53) 66.7 (106) 0.52 (0.31 to 0.87) 0.57 (0.28 to 1.27)
Belief on required
Within 24 h 48.8 (60) 51.2 (63) 1.00 1.00
Time of visit
24 h or more 29.6 (40) 70.4 (95) 0.44 (0.27 to 0.74) 0.42 (0.23 to 0.78)
How long had symptoms?
Median (IQR) days 3 (1–7) 14 (3.5–56) 0.99 (0.99 to 1.00) 0.99 (0.99 to 1.00)
Baseline EQ-VAS
Mean (SD) 73.2 (17.4) 66.3 (20.6) 1.02 (1.01 to 1.03) 1.01 (0.99 to 1.02)
Age (years)
Mean (SD) 49.8 (17.5) 53.7 (15.9) 0.99 (0.97 to 1.00) 0.99 (0.97 to 1.00)
ED, emergency department; VAS, visual analogue scale.
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and participants’ perceived seriousness of their symp-
toms were signiﬁcant predictors of QoL (EQ-VAS) at
follow-up in the univariate analysis (table 4). Only base-
line EQ-VAS score and employment status were found to
be independent predictors of follow-up QoL in the
adjusted linear regression model which includes the a
priori variables (table 4). Individuals with higher base-
line QoL had higher follow-up QoL and those whose
employment status was ‘other’ (ie, student, unemployed)
showed lower QoL at follow-up compared with employed
participants. In the adjusted model, neither site of pres-
entation nor presenting symptoms were independent
predictors of QoL, although the lower QoL for general
practice was of borderline signiﬁcance (p=0.051).
Subgroup analysis
Combining all ailments, no signiﬁcant difference in pro-
portion resolved was found between sites (table 2).
However, as table 5 indicates for musculoskeletal aches
and pains only, resolution was higher for ED (31.0%)
and pharmacy (28.6%) than for general practice (9.8%;
p=0.045). No difference in the proportion resolved was
found for sore throat/cough cold with 51.2% resolving
from pharmacy and 48.8% from general practice
(p=0.825). There were insufﬁcient numbers to compare
for eye pain/discomfort or for stomach upset (table 5).
Individuals whose symptoms had resolved had signiﬁ-
cantly higher QoL at follow-up than for those with unre-
solved symptoms (table 6). Symptom resolution was also
signiﬁcantly associated with participant satisfaction mea-
sured by the MISS-21 (table 6) and this was driven
mainly by participants recruited from general practices.
In terms of reconsultation following the index consult-
ation, subsequent visits to general practice or pharma-
cies were not signiﬁcantly different for site of
presentation (data not presented: available from
author). Participants whose index consultation occurred
in ED compared with other sites were signiﬁcantly more
likely to return to ED within the following 2 weeks.
Cost-related outcomes
The mean (95% CI) overall cost (sum of total initial
consultation cost and 2-week follow-up costs) was highest
in ED £147.09 (£125.32 to £168.85, n=48) compared
with £82.34 (£63.10 to £101.58, n=115) and £29.30
(£21.60 to £37.00, n=95) in general practice and phar-
macy, respectively. The mean follow-up QALY score was
estimated to be highest for pharmacy participants
(a score was estimated for 67.9% of participants, n=91),
compared with those in general practice (63.0%, n=102)
and ED (55.6%, n=45), although this could partially be
accounted for by the fact that they had the highest
mean score at the initial visit (this is adjusted for in the
subsequent regression analysis).
The number of respondents contributing to the mean
incremental cost analysis was 44/81 (54.3%) for ED,
108/162 (66.7%) for general practice and 91/134
(67.9%) for pharmacy; these rates did not differ
signiﬁcantly across the three settings (p=0.10). After
adjusting for age, gender, baseline EQ-5D-3L score and
type of ailment, the mean cost was estimated to be
lowest for pharmacy participants; mean (95% CI) incre-
mental costs (compared with pharmacy) were estimated
to be £57.04 (£34.95 to £79.12; general practice;
p<0.001) and £113.63 (£81.78 to £145.47; ED; p<0.001).
After adjusting for age, gender, baseline EQ-5D-3L utility
score, type of ailment, employment status and whether it
was the ﬁrst time they had experienced the illness, the
mean QALY score was estimated to be highest for phar-
macy participants, though there were no signiﬁcant dif-
ferences between or across settings. The mean (95% CI)
incremental QALY gain for pharmacy participants com-
pared with general practice and ED participants was esti-
mated to be 0.001 (0.000 to 0.002) and 0.001 (−0.001 to
0.002), respectively. Looking at costs and effects
together, as pharmacy was estimated to be less costly and
as effective (in terms of symptom resolution) compared
with ED and general practice, it can be said to dominate
both of these options. It should however be noted that
there were no signiﬁcant differences in outcomes
between any of the groups.
Triggers for seeking care
The main predeﬁned triggers for choice of site were
location and convenience of not having to travel too far
(table 7). For participants who visited ED, the fact that
they would have to wait longer for an appointment with
a general practice ranked highly (rank 2, 37%). Those
visiting a pharmacy felt their symptoms were not serious
enough to consult a doctor (rank 3, 51.5%), while those
visiting the general practice, 63.6% (rank 2) felt their
symptoms were not serious enough for ED. The triggers
differed across sites and although ‘site in a convenient
location’ was a popular choice for participants recruited
from all three types of site, it was more common in phar-
macy (79.1%, n=106). ‘Knowing the staff’ was given as a
reason in a higher proportion (45.7%, n=74) of those
visiting the general practice compared with other set-
tings. Participants were more likely to seek care from ED
if they had not experienced the symptom previously or
if the symptom was of recent onset (table 1). The
former suggests that previous experience may affect
decision-making regarding health-seeking behaviour.
DISCUSSION
Principal findings
This is the ﬁrst study to compare the health-related and
cost-related outcomes associated with the management
of minor ailments in these three healthcare settings:
EDs, general practices and community pharmacies.
Symptom resolution and mean improvement in QoL was
similar across participants from all settings suggesting
equivalence in health outcome. While the absolute rate
of symptom resolution appeared to be better in phar-
macy, the overall lower than anticipated resolution rates
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across all settings, together with reduced numbers of
participants at follow-up, meant that the study was
under-powered to detect whether these differences were
statistically signiﬁcant.
Mean overall costs were signiﬁcantly lower for phar-
macy consultations compared with general practice con-
sultations and with ED consultations which were
associated with the highest costs. The results suggest that
substantial savings could be achieved if demand on ED
and general practice was shifted to the community phar-
macy setting. Some caution is needed because the per-
ceived seriousness and urgency with which to seek care,
as well as whether the participant had experienced the
symptom(s) previously, varied across settings.
Factors which inﬂuenced the patients’ site of choice
were explored using measures of symptom character-
istics, as well as predeﬁned triggers previously shown to
inﬂuence care-seeking behaviour.11 In this study, the
Table 4 Factors affecting QoL (EQ-VAS) at follow-up
Per cent (n) within variable Mean (SD)
Univariate Adjusted linear regression (R
2=33%)
p Value Coefficient 95% CI p Value
Constant term 54.0 (38.1 to 56.6)
Site
Pharmacy 80.9 (15.3) 0.054* Ref
General practice 75.5 (19.5) −4.58 (−9.19 to 0.02) 0.051
ED 74.8 (19.6) −3.61 (−9.72 to 2.49) 0.245
Ailment
Musculoskeletal aches/pains 73.1 (19.4) 0.005† Ref
Eye pain/discomfort 81.2 (16.5) 1.56 (−4.66 to 7.79) 0.622
Stomach upset 84.7 (11.2) 7.22 (−1.92 to 16.4) 0.121
URT 81.8 (16.5) 4.61 (−0.38 to 9.60) 0.070
Multiple ailments 74.8 (18.4) 5.33 (−2.65 to 13.3) 0.189
Gender
Male 76.6 (18.2) 0.536‡ Ref
Female 78.0 (18.2) −0.12 (−4.25 to 4.02) 0.956
Employment
Employed 80.6 (15.9) 0.010* Ref
Retired 74.9 (18.7) −3.28 (−8.99 to 2.43) 0.259
Other (including student, unemployed) 70.6 (23.1) −8.27 (−14.0 to−2.55) 0.005
Marital status
Single 78.9 (17.1) 0.736†
Married/living with partner 77.5 (18.6)
Divorced/separated/widowed 75.8 (18.1)
Live alone
Yes 77.6 (18.7) 0.898‡
No 77.2 (16.6)
First time experienced illness?
Yes 76.1 (18.9) 0.159‡
No 79.4 (17.1)
How serious?
Not serious at all 82.5 (14.1) <0.001‡ Ref
Somewhat/very serious 74.7 (19.7) −0.55 (−5.05 to 3.96) 0.811
Belief on required
Within 24 h 79.4 (16.9) 0.075‡
Time of visit
24 h or more 75.3 (19.3)
Correlation
How long had ailment?
(Days) −0.262§ <0.001 −0.001 (−0.002 to 0.000) 0.163
Baseline EQ-VAS 0.503§ <0.001 0.47 (0.37 to 0.57) <0.001
Age
(Years) −0.059§ 0.343 −0.11 (−0.27 to 0.5) 0.181
Mean (SD) presented as convention for QoL, but testing may be non-parametric dependent on other assumptions.
*Kruskal-Wallis test.
†ANOVA.
‡Independent t test.
§Spearman’s rank correlation.
ANOVA, analysis of variance; ED, emergency department; QoL, quality of life; URT, upper respiratory tract; VAS, visual analogue scale.
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majority (64.2%) of ED users were experiencing the
symptom for the ﬁrst time with a median onset of one
day, perceived it to be somewhat/very serious (83.1%)
and concluded that a visit to a health service provider
was needed within 24 h. These characteristics differen-
tiated ED users from general practice and community
pharmacy users. Pharmacy users would have either pre-
sented with a direct product request or with a symptom
presentation. The former scenario could suggest that
the user was familiar with the condition for which they
required treatment while the latter would suggest a lack
of familiarity with treatment options for the symptom.
As such, this may have introduced a bias into the types
of user seeking care from community pharmacies. The
type of presentation (direct product request/symptom
presentation) was not documented during the recruit-
ment process. This study relied on each patient’s percep-
tion and self-reporting of their symptoms and did not
include any qualitative exploration of these perceptions
and health-seeking behaviour. Evidence is needed
regarding the key determinants of patients’ health-
seeking behaviour for minor ailments in general and
from the ED setting in particular because of the high
costs associated with this setting. Theory-based studies
are needed to identify key modiﬁable determinants of
this behaviour which in turn will lead to the identiﬁca-
tion of behaviour change strategies to target these
determinants.
Convenience of location and shorter travelling dis-
tances were the most important predeﬁned triggers for
the choice of healthcare setting. Among ED partici-
pants, one of the major reasons cited for choosing the
ED was the expected longer wait to see a general practi-
tioner (GP), which may support the ﬁnding that con-
venience was a major factor in selecting the site of
treatment, or that participants may have thought it was
urgent, or both. The use of EDs for non-urgent condi-
tions has been shown to be associated with fewer avail-
able primary care providers (not pharmacies)20 but the
vast majority of participants in the current study were
registered with a GP so would have had access to general
practice services if they had opted to do so.
The positive association between participant satisfac-
tion and symptom resolution is an important ﬁnding.
An earlier study of acute minor illness where index visits
were made to EDs, family physicians or walk-in clinics,
showed patient satisfaction with patient-centred care was
associated with reduced reutilisation rates.12 Doctors’
communication behaviour is a major driver of patient
satisfaction with GP consultations.21 This emphasises the
need for good consultation skills among healthcare pro-
fessionals. Suboptimal communication during commu-
nity pharmacy consultations has been highlighted as an
area for improvement22 23 because it is associated with
suboptimal and inappropriate outcomes.23–25
Other studies have compared combinations of settings,
for example, walk-in clinics versus family practice versus
ED,12 13 but no previous study included community
pharmacy as a comparator. This study did not explore
whether the patients were seeking care for reasons other
than their minor ailment, however, the promotional
materials clearly speciﬁed the four ailments of interest
and as such, an assumption of this study is that the
minor ailment was the primary reason for presentation.
The inclusion of different types (independent single
outlets, small/large chains) of pharmacies, as well as a
variety of locations (urban/rural) of pharmacies and
general practices, increased the generalisability of the
results. The participants’ choice of setting had face valid-
ity; symptoms that were perceived as somewhat serious
(and therefore might be more worrying and require
expert medical attention) presented more often in ED
than in other settings. All participating sites were within
25 miles of a major city, therefore the results may not be
generalisable to people living in more remote areas.
People in these areas may behave differently when man-
aging their symptoms, especially if convenience is a
major inﬂuencing factor for them too. Both EDs were
located in teaching hospitals and as such, the results
may not be generalisable to EDs in other types of
Table 5 Resolution of symptoms by ailment
Overall ED
General
practice Pharmacy
% (n) % (n) % (n) % (n) p Value
Resolution of symptoms
Musculoskeletal aches and pains (n=118) (n=42) (n=41) (n=35) 0.045*
Resolved 22.9 (27) 31.0 (13) 9.8 (4) 28.6 (10)
Sore throat/cough cold (n=82) – (n=41) (n=41) 0.825*
Resolved 50.0 (41) – 48.8 (20) 51.2 (21)
Eye pain/discomfort† (n=30) (n=7) (n=12) (n=11) –
Resolved 73.3 (22) 71.4 (5) 83.3 (10) 63.6 (7)
Stomach upset† (n=11) (n=1) (n= 6) (n= 4) –
Resolved 63.6 (7) 100 (1) 50.0 (3) 75.0 (3)
*Pearson χ2 test.
†Insufficient power statistical test.
ED, emergency department.
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Table 6 Quality of life and MISS 21 outcomes by symptom resolution
ALL ED General practice Pharmacy
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
EQ-5D-3L utility baseline
Resolved 101 0.74 (0.22) 18 0.58 (0.28) 40 0.76 (0.22) 43 0.79 (0.17)
Not resolved 148 0.64 (0.28) 29 0.49 (0.32) 69 0.64 (0.26) 50 0.73 (0.26)
p Value* 0.002 0.362 0.01 0.195
EQ-5D-3L utility follow-up
Resolved 99 0.93 (0.12) 18 0.94 (0.09) 39 0.95 (0.10) 42 0.91 (0.15)
Not resolved 150 0.71 (0.26) 30 0.62 (0.31) 67 0.71 (0.27) 35 0.77 (0.22)
p Value* <0.001 <0.001 <0.001 <0.001
EQ-VAS baseline
Resolved 103 73.2 (17.4) 19 73.1 (18.0) 41 72.6 (17.8) 43 73.7 (17.2)
Not resolved 158 66.3 (20.6) 32 64.5 (24.2) 72 64.6 (19.8) 54 70.0 (19.2)
p Value* 0.004 0.187 0.034 0.285
EQ-VAS follow-up
Resolved 103 86.3 (11.6) 19 81.5 (14.1) 41 87.0 (10.6) 43 87.7 (11.1)
Not resolved 157 71.5 (19.4 31 70.8 (21.6) 73 69.0 (20.5) 54 75.4 (16.1)
p Value* <0.001 0.061 <0.001 <0.001
n Median (IQR) n Median (IQR) n Median (IQR) n Median (IQR)
Experience
Resolved 100 10 (8–10) 18 9.5 (7.75–10) 41 10 (9–10) 41 10 (8–10)
Not resolved 155 10 (8–10) 30 9 (7.75–10) 73 10 (8–10) 52 10 (8.25–10)
p Value† 0.77 0.46 0.958 0.201
MISS 21 scores
TOTAL score
Resolved 90 5.38 (4.71–6.15) 15 5.48 (4.95–6.62) 37 6.05 (5.19–6.69) 38 4.74 (4.14–5.48)
Not resolved 119 5.00 (4.48–5.90) 26 5.31 (4.79–6.01) 56 5.19 (4.81–6.37) 37 4.43 (4.00–5.02)
p Value† 0.047 0.291 0.015 0.116
Distress
Resolved 90 5.00 (4.17–6.00) 15 5.50 (5.00–7.00) 37 6.00 (5.00–7.00) 38 4.17 (4.00, 5.00)
Not resolved 119 4.67 (4.0–5.67) 26 5.33 (4.46–6.08) 56 5.19 (4.21–6.0) 37 4.00 (3.92, 4.50)
p Value† 0.009 0.074 0.004 0.046
Communication
Resolved 90 5.00 (4.75–6.75) 15 5.50 (5.00–7.00) 37 6.50 (5.25–7.00) 38 5.00 (4.25, 6.25)
Not resolved 119 5.00 (4.50–6.25) 26 5.13 (4.69–6.50) 56 5.50 (5.00–7.00) 37 4.75 (4.13, 5.50)
p Value† 0.161 0.348 0.153 0.206
Rapport
Resolved 90 5.38 (4.50–6.28) 15 5.75 (4.75–6.75) 37 6.00 (5.38–6.88) 38 4.56 (4.22, 5.38)
Not resolved 119 5.00 (4.75–6.00) 26 5.44 (4.84–6.31) 56 5.25 (4.88–6.88) 37 4.75 (4.00, 5.06)
p Value† 0.834 0.668 0.403 0.5
Compliance intent
Resolved 90 5.50 (4.92–6.67) 15 6.00 (5.00–6.67) 37 6.00 (5.00–7.00) 38 5.00 (4.00, 6.00)
Not resolved 119 5.00 (4.33–6.00) 26 5.17 (4.33–6.00) 56 5.33 (5.00–6.33) 37 4.43 (4.00, 5.00)
p Value† 0.057 0.119 0.12 0.136
*Independent samples t test for resolved versus not resolved.
†Mann-Whitney test for resolved versus not resolved.
ED, emergency department; MISS 21, Medicine Information Satisfaction Score; VAS, visual analogue scale.
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hospital. There was slight under-recruitment from com-
munity pharmacies. This study used a cohort design
rather than randomised controlled trial design because
the latter was an impractical option to address the
objectives of this study. Previous research identiﬁed that
perceptions of service quality inﬂuence care seeking from
EDs26 and that competence and credibility of staff was
important and more highly rated for staff in EDs com-
pared with general practices. The current study did not
include measures of quality perception nor assess partici-
pants’ perceptions of staff credibility or competence.
Meaning of the study
Despite the limitations of this study in terms of sample
size, reliance on self-reported data and focusing on
selected common symptoms, the results provide evi-
dence of the value of community pharmacy as a
resource from the management of these types of condi-
tions. The Keogh report highlighted the ‘intense,
growing and unsustainable pressure’ being placed on
EDs and the need to direct demand outside of hospitals
for conditions that may be ‘urgent but non-life threaten-
ing’.3 The same report identiﬁed that community
Table 7 Triggers for choice of site
Per cent (n) unless specified
ED General practice Pharmacy
p Value*(N=81) Rank (N=162) Rank (N=134) Rank
Location and time
The ‘site ’is in a location convenient for me† 51.9 (42) 1 69.1 (112) 1 79.1(106) 1 <0.001
Did not have to travel far to visit the ‘site’† 34.6 (28) 3 51.2 (83) 3 57.4 (77) 2 <0.001
I was already visiting ‘site ’for different reason† 2.5 (2) 17 6.8 (11) 16 35.8 (48) 7 <0.001
It was not convenient to go to the chemist 1.2 (1) 19 1.9 (3) 18 NA – Low counts
It was not convenient to go to the GP 13.6 (11) 11 NA – 15.7 (21) 17 0.837
I can get treatment/advice at ‘site ’without
appointment
NR – NA – 36.6 (49) 6
Knowing the staff
I know the ‘staff ’here† 1.2 (1) 19 45.7 (74) 5 26.9 (36) 11 <0.001
I feel the ‘staff ’here know me† 3.7 (3) 14 30.9 (50) 10 19.4 (26) 14 <0.001
I am comfortable discussing my illness with ‘staff’
here†
23.5 (19) 8 51.2 (83) 3 47.8 (64) 4 <0.001
‘staff’ in ‘site’ in general know about this illness† 25.9 (21) 7 41.4 (67) 6 30.6 (41) 8.5 0.037
I have previously successfully used ‘site’ to treat this
illness†
16.0 (13) 9 32.1 (52) 9 38.1 (51) 5 0.003
I could discuss my illness with ‘staff’ in private† 13.6 (11) 11 39.5 (64) 7 21.6 (29) 12 <0.001
I needed information about illness from ‘staff’ at
‘site’†
34.6 (28) 3 37.0 (60) 8 20.1 (28) 13 0.009
Other options
My illness was too serious to go to GP 30.9 (25) 5 NA – NR – –
My illness was too serious to go to chemist 27.2 (22) 6 NR – NA – –
My illness was not serious enough for ED NA – 63.6 (103) 2 NR – –
My illness was not serious enough for a doctor NA – NA – 51.5 (69) 3 –
I did not want to waste the doctor’s time NR – NA – 30.6 (41) 8.5 –
I previously consulted GP about illness, but it is not
better
16.0 (13) 9 NA – 18.7 (25) 15 0.775
I previously consulted pharmacy about illness, but it
is not better
3.7 (3) 14 9.9 (16) 15 NA – 0.158
I would have to wait longer for appointment at GP 37.0 (30) 2 NA – 29.9 (40) 10 <0.001
I would have to wait longer for appointment at other
services
NR – 14.8 (24) 13 NR – –
I prefer not to go to ED NA 28.4 (46) 11 NR – –
I prefer not to go to GP 3.7 (3) 14 NA – 11.2 (15) 19 0.097
I prefer not to go to a chemist 4.9 (4) 13 16.7 (27) 12 NA – 0.019
Cost of treatment
It was cheaper to visit than other services† 1.2 (1) 19 6.8 (11) 16 17.9 (24) 16 <0.001
Treatment/advice was cheaper for my illness† 1.2 (1) 19 11.7 (19) 14 14.9 (20) 18 0.006
Advice/referral
I came to get advice/treatment that I had seen in
media†
2.5 (2) 17 0 (0) 19 1.5(2) 20 Low counts
*Pearson χ2 test.
†Item recorded on for all sites.
ED, emergency department; GP, general practitioner; NA, not applicable for that site; NR, item not recorded for that site version.
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pharmacies are an ‘under-utilised resource’3 which
could contribute substantially to reduce the burden on
other healthcare providers. Self-care is the preferred
method of managing minor illness for many patients27
and the need to support patients with self-care has been
acknowledged as a priority.3 The results of this cohort
study suggest that patients with minor ailments present-
ing in community pharmacies will have similar health
outcomes to those in general practice and ED, but that
the costs will be substantially lower with pharmacy-
managed consultations. Redirection of demand needs to
address accessibility, affordability, availability and most
importantly, safety of care.28 Earlier interventions to
promote the self-management of minor illness have had
limited effect;29 few, if any, have adopted a theory-based
approach to exploring behaviour and promoting behav-
iour change.
Unanswered questions and future research
Convenience of location was a major inﬂuence on
health-seeking behaviour for the conditions included in
this study. The evidence for co-locating community phar-
macies with EDs and general practices is currently
lacking, but the co-location of walk-in clinics within EDs
failed to inﬂuence patient satisfaction, preference or
choice.30 Patients’ perceptions that obtaining a GP
appointment would ‘take too long’ is one which requires
further investigation to determine what urgent care
arrangements should be available within general prac-
tices to manage acute conditions perceived to be serious
or in need of immediate attention. The substantially
lower costs associated with pharmacy management of
these ailments, combined with similar health outcomes
across settings, suggest there is an urgent need to iden-
tify effective interventions to promote the use of commu-
nity pharmacies for the management of minor ailments.
These interventions should be evidence-based and
underpinned by behaviour change theory to maximise
their effectiveness and reproducibility. Further research
is warranted and planned regarding patients’ decision-
making processes for choosing their care provider when
managing minor ailments.
Author affiliations
1Division of Applied Health Sciences, Centre of Academic Primary Care,
University of Aberdeen, Aberdeen, UK
2Emergency Department, Aberdeen Royal Infirmary, Aberdeen, UK
3Health Economics Group, Norwich Medical School, Norwich, UK
4Norwich Medical School, University of East Anglia, Norwich, UK
5School of Pharmacy, University of East Anglia, Norwich, UK
Twitter Follow Margaret Watson at @MagsWatson1
Acknowledgements The authors thank the patients and healthcare providers
who participated in this study. They also thank J Burr and J Inch for data
collection and H Riley and N Clark for their administrative support.
Contributors MCW (guarantor) had the original idea for the study and with
JF, CMB, RH, TP, THS and DW designed the trial and formed the investigator
group that obtained funding. MCW, RH and SF were responsible for
overseeing study implementation and AB, VM and VP were responsible for
data collection. SF, THS and GRB conducted the analyses. MCW, SF and GRB
drafted the manuscript which was revised by all authors. All researchers were
independent of the funders and approved the final version.
Funding This work was supported by the Pharmacy Practice Research Trust
which merged with the Pharmaceutical Trust for Educational and Charitable
Objects in December 2012 to form Pharmacy Research UK.
Competing interests None.
Patient consent Obtained.
Ethics approval The North of Scotland Research Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. The College of Emergency Medicine. The drive for quality. How to
achieve safe, sustainable care in our emergency departments?
London: The College of Emergency Medicine, 2013.
2. Health and Social Care Information Centre. Focus on accident and
emergency. http://www.hscic.gov.uk/catalogue/PUB13040/acci-
emer-focu-on-2013-rep-V2.pdf. Updated 2013(accessed 26 Mar
2014).
3. NHS England. Transforming urgent and emergency care services in
England. Urgent and emergency care review end of phase 1 report.
Appendix 1—Revised Evidence Base from the Urgent and
Emergency Care Review. Leeds: NHS England, 2013.
4. Hippisley-Cox J, Vinogradova Y. Trends in consultation rates in
general practice 1995/1996 to 2008/9: analysis of the QResearch
database. Final report to NHS information Centre and Department of
Health. Nottingham: The NHS Information Centre for Health and
Social Care, 2009.
5. Watson MC, Holland R, Ferguson J, et al. Community pharmacy
management of minor illness (the MINA study). London: Pharmacy
Research UK, 2014.
6. Jones R, White R, Armstrong D, et al. Managing acute illnesses:
an enquiry into the quality of general practice in England. London:
The King’s Fund, 2010.
7. The Royal Pharmaceutical Society of Great Britain. RPS e-PIC
references on: prescription only medicines reclassified to pharmacy
only medicines. London: RPSGB, 2008.
8. Paudyal V, Watson MC, Sach T, et al. Are pharmacy-based minor
ailment schemes a substitute for other service providers?
A systematic review. Br J Gen Pract 2013;63:e472–81.
9. EuroQol Research Foundation. EQ-5D. http://www.euroqol.org/
10. Meakin R, Weinman J. The ‘Medical interview satisfaction scale’
(MISS-21) adapted for British general practice. Fam Pract
2002;19:257–63.
11. Porteous T. How do people choose between self-care, supported
self-care and GP consultation in minor illness? [PhD thesis].
University of Aberdeen, 2007.
12. Campbell MK, Silver RW, Hoch JS, et al. Re-utilization outcomes
and costs of minor acute illness treated at family physician offices,
walk-in clinics, and emergency departments. Can Fam Physician
2005;51:82–93.
13. Hutchison B, Østbye T, Barnsley J, et al. Patient satisfaction and
quality of care in walk-in clinics, family practices and emergency
departments: the Ontario walk-in clinic study. Can Med Assoc J
2003;168:977–83.
14. Brooks R, De Charro F. EuroQol: the current state of play. Health
Policy 1996;37:53–72.
15. Schafheutle E, Noyce P, Sheehy C, et al. Evaluation of a pilot
scheme to allow patients exempt from prescription charges to
consult community pharmacists and receive ‘over the counter
’products for minor ailments free of charge under the NHS Direct
Supply by community pharmacists. Edinburgh: Scottish Government,
2002.
16. Briggs A, Clark T, Wolstenholme J, et al. Missing...presumed at random:
cost-analysis of incomplete data. Health Econ 2003;12:377–92.
Watson MC, et al. BMJ Open 2015;5:e006261. doi:10.1136/bmjopen-2014-006261 13
Open Access
 o
n
 29 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2014-006261 on 18 February 2015. Downloaded from 
17. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in
trial-based cost-effectiveness analysis: the importance of controlling
for baseline utility. Health Econ 2005;14:487–96.
18. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the
economic evaluation of health care programmes. 3rd edn. New York:
Oxford University Press, 2005.
19. NICE. Guide to the methods of technology appraisal. London:
National Institute for Health and Care Excellence, 2013.
20. Mathison DJ, Chamberlain JM, Cowan NM, et al. Primary care
spatial density and nonurgent emergency department utilization:
a new methodology for evaluating access to care. Acad Pediatr
2013;13:278–85.
21. Paddison C, Abel G, Roland M, et al. Drivers of overall satisfaction
with primary care: evidence from the English general practice patient
survey. Health Expect 2013. doi:10.1111/hex.12081
22. Which Report. Can you trust your local pharmacy’s advice?WHICH?
20 May 2013. http://www.which.co.uk/news/2013/05/can-you-trust-
your-local-pharmacys-advice-319886/(accessed 23 Jul 2014).
23. Watson MC, Bond CM, Grimshaw J, et al. Factors predicting the
guideline compliant supply (or non-supply) of non-prescription
medicines in the community pharmacy setting. Br Med J
2006;15:53–7.
24. Watson MC, Walker AE, Bond CM. Community pharmacists’ views
and beliefs about the treatment of symptoms suggestive of vaginal
thrush in community pharmacies. Pharm World Sci 2000;22:130–5.
25. Watson MC, Bond CM, Grimshaw JM, et al. Educational strategies
to promote evidence-based community pharmacy practice: a cluster
randomized controlled trial (RCT). Fam Pract 2002;19:529–36.
26. Lo S, Mc Kechnie S. Perceptions of service quality and sacrifice in
patients with minor medical conditions using emergency care.
Int J Clin Pract 2007;61:596–602.
27. Porteous T, Ryan M, Bond CM, et al. Preferences for self-care or
professional advice for minor illness: a discrete choice experiment.
Br J Gen Pract 2006;56:911–17.
28. Durand AMP, Gentile S, Devictor B, et al. ED patients: how
nonurgent are they? Systematic review of the emergency medicine
literature. Am J Emerg Med 2011;29:333–45.
29. Little P, Somerville J, Williamson I, et al. Randomised controlled trial
of self management leaflets and booklets for minor illness provided
by post. BMJ 2001;322:1214–17.
30. Chalder M, Montgomery A, Hollinghurst S, et al. Comparing care at
walk-in centres and at accident and emergency departments:
an exploration of patient choice, preference and satisfaction.
Emerg Med J 2007;24:260–4.
14 Watson MC, et al. BMJ Open 2015;5:e006261. doi:10.1136/bmjopen-2014-006261
Open Access
 o
n
 29 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2014-006261 on 18 February 2015. Downloaded from 
